Ergomed Management

Management Kriterienprüfungen 0/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	1.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	1.6yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Ergomed hat keinen Geschäftsführer, oder es liegen keine verfügbaren Daten vor.

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Miroslav Reljanovic	Founder & Executive Chairman	5.9yrs	UK£964.30k	17.98% £ 102.0m
Michael Spiteri	Chief Transformation & Technology Officer	less than a year	UK£52.77k	keine Daten
Jonathan Curtain	CFO & Executive Director	less than a year	keine Daten	keine Daten
Michael Forstner	Head of Risk Management & Pharmacoepidemiology	5.1yrs	keine Daten	keine Daten
Sally Amanuel	President of PrimeVigilance	no data	keine Daten	keine Daten
Gordana Tonkovic	President of Clinical Research	no data	keine Daten	keine Daten
Ronel Steyn	Senior Vice President of Global Development	1.6yrs	keine Daten	keine Daten
Keith Byrne	Senior Vice-President of Capital Markets & Strategy	1.4yrs	keine Daten	keine Daten
Joanne Bletcher	Company Secretary	no data	keine Daten	keine Daten

1.5yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: 2EMDas Führungsteam des Unternehmens gilt nicht als erfahren (1.5 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Miroslav Reljanovic	Founder & Executive Chairman	5.9yrs	UK£964.30k	17.98% £ 102.0m
Jonathan Curtain	CFO & Executive Director	less than a year	keine Daten	keine Daten
Mark Enyedy	Independent Non-Executive Director	2yrs	UK£52.72k	keine Daten
Llew Keltner	Independent Non-Executive Director	2.2yrs	UK£52.72k	keine Daten
Anne Michelle Whitaker	Independent Non-Executive Director	less than a year	UK£27.89k	keine Daten
John Dawson	Senior Independent Director	1.3yrs	UK£49.15k	keine Daten

1.6yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: 2EMDie Vorstandsmitglieder gelten nicht als erfahren ( 1.6 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Ergomed Management

Management Kriterienprüfungen 0/4

Wichtige Informationen

Jüngste Management Updates

Ergomed plc, Annual General Meeting, Jun 22, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Ergomed plc, Annual General Meeting, Jun 22, 2023

Full year 2022 earnings released: EPS: UK£0.30 (vs UK£0.26 in FY 2021)

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Now 21% undervalued after recent price drop

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings released: EPS: UK£0.26 (vs UK£0.20 in FY 2020)

Ergomed plc, Annual General Meeting, Jun 10, 2022

Less than half of directors are independent

Now 21% undervalued

Full year 2021 earnings released: EPS: UK£0.26 (vs UK£0.20 in FY 2020)

Investor sentiment improved over the past week

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Investor sentiment improved over the past week

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Investor sentiment improved over the past week

Non-Executive Director has left the company

Investor sentiment improved over the past week

Full year 2020 earnings released

New 90-day high: €14.15

Ergomed plc to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: €13.40

New 90-day high: €12.10

Ergomed plc (AIM:ERGO) acquired MedSource Consulting Inc. for $25 million.

New 90-day high: €9.76

New 90-day high: €9.58

New 90-day high - €7.68

New 90-day high - €6.86

Ergomed plc to Report First Half, 2020 Results on Sep 22, 2020

New 90-day high - €6.60

Geschäftsführer

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter